<DOC>
	<DOCNO>NCT01273805</DOCNO>
	<brief_summary>Hydroxychloroquine approve treatment non-cancerous illness rheumatoid arthritis systemic lupus erythematous . Researchers laboratory test tumor patient pancreatic cancer discover certain pathway inside cell promote growth survival tumor . Hydroxychloroquine may inactivate pathway result death pancreatic cancer cell .</brief_summary>
	<brief_title>Hydroxychloroquine Previously Treated Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Every 4 week consider one cycle . Participants begin take hydroxychloroquine orally twice per day start Cycle 1 Day 1 . They need return clinic every two week blood test see doctor nurse practitioner . Participants may remain study indefinitely long best interest . They CT scan every 8 week help determine cancer grow stay .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Histologically confirm unresectable pancreatic adenocarcinoma metastatic distant sit Measurable disease , define least one lesion accurately measure least one dimension Patients must treat one two previous line chemotherapy metastatic disease document tumor progression intolerance due toxicity Minimum two week since major surgery , completion radiation , completion prior systemic anticancer therapy 18 year age old Life expectancy great 12 week ECOG performance status 0 , 1 2 Normal organ marrow function outline protocol Patients must able swallow pill Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Participants chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 4 week earlier . More two previous chemotherapy regimen treatment metastatic pancreatic cancer Uncontrolled brain leptomeningeal metastases History macular degeneration , visual field change , retinal disease , cataract would interfere funduscopic eye examination History allergic reaction attribute compound similar chemical biologic composition hydroxychloroquine Previous treatment chloroquine hydroxychloroquine indication , rheumatoid arthritis , SLE malaria prophylaxis Prior treatment investigational drug within precede 4 week Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption hydroxychloroquine . Patients undergone Whipple procedure localize pancreatic cancer exclude enrollment History noncompliance medical regimen Known diagnosis glucose6phosphate deficiency , porphyria psoriasis Penicillamine use Wilson 's disease indication Uncontrolled intercurrent illness include limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 3years deemed investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past three year : cervical cancer situ , basal cell squamous cell carcinoma HIVpositive individual combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>hydroxychloroquine</keyword>
</DOC>